Leukaemia - chronic myeloid leukaemia

The PBS subsidises asciminib and ponatinib for patients with chronic myeloid leukaemia (CML).

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with asciminib and ponatinib under the National Health Act 1953, section 85 for patients with chronic myeloid leukaemia (CML).

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing asciminib and ponatinib.

Authority applications

Applying for initial treatment

Asciminib for patients with T315I mutation

Applications for initial authority approval to prescribe PBS-subsidised asciminib to treat CML can be made either in:

All written applications must include the completed:

Asciminib for patients without T315I mutation

Applications for initial authority approval to prescribe PBS-subsidised asciminib to treat CML can be made either:

Applying for continuing treatment

Asciminib for patients with T315I mutation

Applications for continuing authority approval to prescribe PBS-subsidised asciminib to treat CML can be made either in:

All written applications must include the completed:

Asciminib for patients without T315I mutation

Continuing PBS-subsidised treatment with asciminib is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

Ponatinib

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised ponatinib to treat CML can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for first continuing authority approval to prescribe PBS-subsidised ponatinib to treat CML can be made either in:

All written applications must include the completed:

After we approve the first continuing application for ponatinib treatment, subsequent continuing applications can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 17 June 2024.
QC 33151